HOB Biotech released its 2026 interim report, with net profit attributable to the parent company of 16.6776 million yuan, up 37.05% from the same period last year. Total operating revenue was 196 million yuan, up 3.22% year-on-year; net cash inflow from operating activities was 37.2862 million yuan, up 60.20% year-on-year. The company's latest asset-liability ratio was 9.29%, down 7.55 percentage points from the same period last year; gross margin was 60.34%, up 1.16 percentage points year-on-year; diluted earnings per share was 0.27 yuan, up 42.11% year-on-year.
HOB Biotech Group Corp LtdNet profit up 37.05% and EPS up 42.11% in interim report.